Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial. (2019)
Attributed to:
A Programme for ALS Care in Europe (ALS-CarE)
funded by
ESRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1080/21678421.2019.1632899
PubMed Identifier: 31284774
Publication URI: http://europepmc.org/abstract/MED/31284774
Type: Journal Article/Review
Volume: 20
Parent Publication: Amyotrophic lateral sclerosis & frontotemporal degeneration
Issue: 7-8
ISSN: 2167-8421